254 related articles for article (PubMed ID: 22689013)
21. Both invariant chain isoforms Ii31 and Ii41 promote class II antigen presentation.
Serwe M; Reuter G; Sponaas A; Koch S; Koch N
Int Immunol; 1997 Jul; 9(7):983-91. PubMed ID: 9237107
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of tolerance induction in major histocompatibility complex class II-restricted T cells specific for a blood-borne self-antigen.
Zal T; Volkmann A; Stockinger B
J Exp Med; 1994 Dec; 180(6):2089-99. PubMed ID: 7964486
[TBL] [Abstract][Full Text] [Related]
23. Exit of major histocompatibility complex class II-invariant chain p35 complexes from the endoplasmic reticulum is modulated by phosphorylation.
Kuwana T; Peterson PA; Karlsson L
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):1056-61. PubMed ID: 9448284
[TBL] [Abstract][Full Text] [Related]
24. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
Bodey B; Bodey B; Kaiser HE
In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
[TBL] [Abstract][Full Text] [Related]
25. Comparison of thymocyte development in normal and invariant chain-deficient mice provides evidence that maturation-related changes in TCR and co-receptor levels play a critical role in cell fate.
Huang LY; van Meerwijk JP; Bikoff EK; Germain RN
Int Immunol; 1996 Sep; 8(9):1429-40. PubMed ID: 8921421
[TBL] [Abstract][Full Text] [Related]
26. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
27. Business as usual: the p35 isoform of human CD74 retains function in antigen presentation.
Bergmann H
Immunol Cell Biol; 2012 Oct; 90(9):839-40. PubMed ID: 23032370
[No Abstract] [Full Text] [Related]
28. Virus-encoded ectopic CD74 enhances poxvirus vaccine efficacy.
Walline CC; Deffit SN; Wang N; Guindon LM; Crotzer VL; Liu J; Hollister K; Eisenlohr LC; Brutkiewicz RR; Kaplan MH; Blum JS
Immunology; 2014 Apr; 141(4):531-9. PubMed ID: 24205828
[TBL] [Abstract][Full Text] [Related]
29. Double-positive thymocytes select mucosal-associated invariant T cells.
Seach N; Guerri L; Le Bourhis L; Mburu Y; Cui Y; Bessoles S; Soudais C; Lantz O
J Immunol; 2013 Dec; 191(12):6002-9. PubMed ID: 24244014
[TBL] [Abstract][Full Text] [Related]
30. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
Ilkovitch D; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2004 Jun; 53(6):525-32. PubMed ID: 14730400
[TBL] [Abstract][Full Text] [Related]
31. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition.
Patel DM; Arnold PY; White GA; Nardella JP; Mannie MD
J Immunol; 1999 Nov; 163(10):5201-10. PubMed ID: 10553040
[TBL] [Abstract][Full Text] [Related]
32. Ex vivo analysis of thymic CD4 T cells in nonobese diabetic mice with tetramers generated from I-A(g7)/class II-associated invariant chain peptide precursors.
Jang MH; Seth NP; Wucherpfennig KW
J Immunol; 2003 Oct; 171(8):4175-86. PubMed ID: 14530340
[TBL] [Abstract][Full Text] [Related]
33. On the role of high- and low-abundance class II MHC-peptide complexes in the thymic positive selection of CD4(+) T cells.
Chmielowski B; Muranski P; Kisielow P; Ignatowicz L
Int Immunol; 2000 Jan; 12(1):67-72. PubMed ID: 10607751
[TBL] [Abstract][Full Text] [Related]
34. Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in vivo.
Beers C; Burich A; Kleijmeer MJ; Griffith JM; Wong P; Rudensky AY
J Immunol; 2005 Feb; 174(3):1205-12. PubMed ID: 15661874
[TBL] [Abstract][Full Text] [Related]
35. Difference in antigen presentation pathways between cortical and medullary thymic epithelial cells.
Kasai M; Hirokawa K; Kajino K; Ogasawara K; Tatsumi M; Hermel E; Monaco JJ; Mizuochi T
Eur J Immunol; 1996 Sep; 26(9):2101-7. PubMed ID: 8814253
[TBL] [Abstract][Full Text] [Related]
36. The D-6 mouse monoclonal antibody recognizes the CD74 cytoplasmic tail.
Genève L; Gauthier C; Thibodeau J
Monoclon Antib Immunodiagn Immunother; 2014 Aug; 33(4):221-7. PubMed ID: 25171001
[TBL] [Abstract][Full Text] [Related]
37. The antigen presentation pathway in medullary thymic epithelial cells, but not that in cortical thymic epithelial cells, conforms to the endocytic pathway.
Kasai M; Kominami E; Mizuochi T
Eur J Immunol; 1998 Jun; 28(6):1867-76. PubMed ID: 9645368
[TBL] [Abstract][Full Text] [Related]
38. Major histocompatibility class II peptide occupancy, antigen presentation, and CD4+ T cell function in mice lacking the p41 isoform of invariant chain.
Takaesu NT; Lower JA; Robertson EJ; Bikoff EK
Immunity; 1995 Sep; 3(3):385-96. PubMed ID: 7553002
[TBL] [Abstract][Full Text] [Related]
39. The pathway for MHCII-mediated presentation of endogenous proteins involves peptide transport to the endo-lysosomal compartment.
Dani A; Chaudhry A; Mukherjee P; Rajagopal D; Bhatia S; George A; Bal V; Rath S; Mayor S
J Cell Sci; 2004 Aug; 117(Pt 18):4219-30. PubMed ID: 15316082
[TBL] [Abstract][Full Text] [Related]
40. Relaxed DM requirements during class II peptide loading and CD4+ T cell maturation in BALB/c mice.
Bikoff EK; Wutz G; Kenty GA; Koonce CH; Robertson EJ
J Immunol; 2001 Apr; 166(8):5087-98. PubMed ID: 11290790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
